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Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute illness are
associated with a risk of venous thromboembolism (VTE).
Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are
intended to support patients, clinicians, and other health care professionals in decisions about the use of
anticoagulation for thromboprophylaxis for patients with COVID-19–related critical illness and acute
illness who do not have confirmed or suspected VTE.
Methods: ASH formed a multidisciplinary guideline panel and applied strict management strategies to
minimize potential bias from conflicts of interest. The panel included 3 patient representatives. The McMaster
University GRADE Centre supported the guideline-development process, including performing systematic
evidence reviews (up to 19 August 2020). The panel prioritized clinical questions and outcomes according to
their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to
assess evidence and make recommendations, which were subject to public comment.
Results: The panel agreed on 2 recommendations. The panel issued conditional recommendations in favor
of prophylactic-intensity anticoagulation over intermediate-intensity or therapeutic-intensity anticoagulation for
patients with COVID-19–related critical illness or acute illness who do not have confirmed or suspected VTE.
Conclusions: These recommendations were based on very low certainty in the evidence, underscoring
the need for high-quality, randomized controlled trials comparing different intensities of anticoagulation.
They will be updated using a living recommendation approach as new evidence becomes available.
Submitted 5 November 2020; accepted 18 December 2020; published online 8
February 2021. DOI 10.1182/bloodadvances.2020003763.
*A.C. and E.K.T. are joint first authors.
The full-text version of this article contains a data supplement.
© 2021 by The American Society of Hematology
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Summary of recommendations
Patients with COVID-19, which is caused by the novel severe acute
respiratory distress syndrome coronavirus 2, may develop hemostatic
abnormalities.1-4 Early reports demonstrated high rates of VTE for
patients who are acutely ill or hospitalized with COVID-19,
including those receiving critical care.5 The optimal strategy for
thromboprophylaxis in these patients remains uncertain.
These guidelines are based on updated and original system-
atic reviews of evidence conducted under the direction of the
McMaster University GRADE Centre with international collabo-
rators. The panel followed best practices for guideline develop-
ment recommended by the Institute of Medicine and the
Guidelines International Network (GIN).6-8 The panel used the
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach9-15 to assess the certainty in the
evidence and formulate recommendations. The recommenda-
tions are listed in Table 1.
Interpretation of strong and
conditional recommendations
The strength of a recommendation is expressed as either strong
(“the guideline panel recommends...”), or conditional (“the guideline
panel suggests…”) and has the following interpretation:
Strong recommendation
c For patients: Most individuals in this situation would want
the recommended course of action, and only a small proportion
would not.
c For clinicians: Most individuals should follow the recommended
course of action. Formal decision aids are not likely to be needed
to help individual patients make decisions consistent with their
values and preferences.
c For policy makers: The recommendation can be adopted as
policy in most situations. Adherence to this recommendation
according to the guideline could be used as a quality criterion or
performance indicator.
c For researchers: The recommendation is supported by credible
research or other convincing judgments that make additional
research unlikely to alter the recommendation. On occasion, a
strong recommendation is based on low or very low certainty in
the evidence. In such instances, further research may provide
important information that alters the recommendations.
Conditional recommendation
c For patients: The majority of individuals in this situation would want
the suggested course of action, but many would not. Decision aids
may be useful in helping patients to make decisions consistent with
their individual risks, values, and preferences.
Table 1. Recommendations
Recommendation Remarks
Recommendation 1. The ASH guideline panel suggests using
prophylactic-intensity over intermediate-intensity or therapeutic-
intensity anticoagulation for patients with COVID-19–related
critical illness who do not have suspected or confirmed VTE
(conditional recommendation based on very low certainty in the
evidence about effects Å◯◯◯)
• Between the time this recommendation was published online (27 October 2020) and when it was published in Blood
Advances, a press release (https://www.nih.gov/news-events/news-releases/nih-activ-trial-blood-thinners-pauses-
enrollment-critically-ill-covid-19-patients) describing the results of a planned interim analysis of 3 randomized
controlled trials, REMAP-CAP, ACTIV-4, and ATTACC (NCT 02735707, 04505774, and 04372589, respectively),
was issued. In these trials, therapeutic-intensity anticoagulation was compared with prophylactic-intensity
anticoagulation for patients with COVID-19–related critical illness. The ASH guideline panel plans to update this
recommendation when the full results of REMAP-CAP, ACTIV-4, and ATTACC become available. Clinicians should
weigh the potential benefits and harms based on the most up-to-date available evidence in caring for their patients.
• Patients with COVID-19–related critical illness are defined as those suffering from an immediately life-threatening
condition who would typically be admitted to an intensive care unit. Examples include patients requiring hemodynamic
support, ventilatory support, and renal replacement therapy.
• An individualized assessment of the patient’s risk of thrombosis and bleeding is important when deciding on
anticoagulation intensity; risk-assessment models to estimate thrombotic and bleeding risk are available, but they have
not been validated for patients with COVID-19; the panel acknowledges that higher-intensity anticoagulation may be
preferred for patients judged to be at high thrombotic risk and low bleeding risk
•At present, there is no direct high-certainty evidence comparing different types of anticoagulants; the selection of a specific
agent (eg, low-molecular-weight heparin, unfractionated heparin, etc) may be based on availability, resources required,
familiarity, and the aim of minimizing PPE use or staff exposure to COVID-19–infected patients as well as patient-specific
factors (eg, renal function, history of heparin-induced thrombocytopenia, concerns about gastrointestinal tract absorption)
• This recommendation does not apply to patients who require anticoagulation to prevent thrombosis of extracorporeal
circuits such as those on ECMO or CRRT
Recommendation 2. The ASH guideline panel suggests using
prophylactic-intensity over intermediate-intensity or therapeutic-
intensity anticoagulation for patients with COVID-19–related
acute illness who do not have suspected or confirmed VTE
(conditional recommendation based on very low certainty in the
evidence about effects Å◯◯◯)
• Between the time this recommendation was published online (27 October 2020) and when it was published in Blood
Advances, a press release (https://www.nih.gov/news-events/news-releases/full-dose-blood-thinners-decreased-need-
life-support-improved-outcome-hospitalized-covid-19-patients) describing the results of a planned interim analysis of 3
randomized controlled trials, REMAP-CAP, ACTIV-4, and ATTACC (NCT 02735707, 04505774, and 04372589,
respectively), was issued. In these trials, therapeutic-intensity anticoagulation was compared with prophylactic-intensity
anticoagulation for moderately ill hospitalized patients with COVID-19. The ASH guideline panel plans to update this
recommendationwhen the full results of REMAP-CAP, ACTIV-4, andATTACCbecome available. Clinicians shouldweigh
the potential benefits and harms based on the most up-to-date available evidence in caring for their patients.
• Patients with COVID-19–related acute illness are defined as those with clinical features that would typically result
in admission to a medicine inpatient ward without requirement for advanced clinical support. Examples include
patients with dyspnea or mild to moderate hypoxia.
• An individualized assessment of the patient’s risk of thrombosis and bleeding is important when deciding on
anticoagulation intensity; risk-assessment models to estimate thrombotic and bleeding risk are available, but they
have not been validated for patients with COVID-19; the panel acknowledges that higher-intensity anticoagulation
may be preferred for patients judged to be at high thrombotic risk and low bleeding risk
• At present, there is no direct high-certainty evidence comparing different types of anticoagulants; the selection of a specific
agent (eg, low-molecular-weight heparin, unfractionated heparin, etc) may be based on availability, resources required,
familiarity, and the aim of minimizing PPE use or staff exposure to COVID-19–infected patients as well as patient-specific
factors (eg, renal function, history of heparin-induced thrombocytopenia, concerns about gastrointestinal tract absorption)
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c For clinicians: Recognize that different choices will be appropriate
for individual patients and that youmust help each patient arrive at a
management decision consistent with their values and preferences.
Decision aidsmay be useful in helping individuals tomake decisions
consistent with their individual risks, values, and preferences.
c For policy makers: Policy-making will require substantial debate and
involvement of various stakeholders. Performance measures about
the suggested course of action should focus on whether an
appropriate decision-making process is duly documented.
c For researchers: This recommendation is likely to be strength-
ened (for future updates or adaptation) by additional research.
An evaluation of the conditions and criteria (and the related
judgments, research evidence, and additional considerations)
that determined the conditional (rather than strong) recom-
mendation will help identify possible research gaps.
Recommendations
Recommendation 1. The American Society of Hematology
(ASH) guideline panel suggests using prophylactic-intensity over
intermediate-intensity or therapeutic-intensity anticoagulation for
patients with coronavirus disease 2019 (COVID-19)–related critical
illness who do not have suspected or confirmed venous thromboem-
bolism (VTE) (conditional recommendation based on very low certainty
in the evidence about effects Å◯◯◯).
Remarks:
c Between the time this recommendation was published online (27
October 2020) and when it was published in Blood Advances, a
press release (https://www.nih.gov/news-events/news-releases/
nih-activ-trial-blood-thinners-pauses-enrollment-critically-ill-covid-19-
patients) describing the results of a planned interim analysis of 3
randomized controlled trials, REMAP-CAP, ACTIV-4, and ATTACC
(NCT 02735707, 04505774, and 04372589, respectively), was
issued. In these trials, therapeutic-intensity anticoagulation was
compared with prophylactic-intensity anticoagulation for patients
with COVID-19–related critical illness. The ASH guideline panel
plans to update this recommendation when the full results of
REMAP-CAP, ACTIV-4, and ATTACC become available. Clinicians
should weigh the potential benefits and harms based on the most
up-to-date available evidence in caring for their patients.
c Patients with COVID-19–related critical illness are defined as those
suffering from an immediately life-threatening condition who
would typically be admitted to an intensive care unit (ICU).
Examples include patients requiring hemodynamic support,
ventilatory support, and renal-replacement therapy.
c An individualized assessment of the patient’s risk of thrombosis and
bleeding is important when deciding on anticoagulation intensity.
Risk-assessment models to estimate thrombotic and bleeding risk
in hospitalized patients are available, but they have not been
validated for patients with COVID-19. The panel acknowledges that
higher-intensity anticoagulation may be preferred for patients
judged to be at high thrombotic risk and low bleeding risk.
c At present, there is no direct high-certainty evidence comparing
different types of anticoagulants. The selection of a specific agent
(eg, low-molecular-weight heparin, unfractionated heparin, etc) may
be based on availability, resources required, familiarity, and the aim
of minimizing personal protective equipment (PPE) use or staff ex-
posure to COVID-19–infected patients as well as patient-specific
factors (eg, renal function, history of heparin-induced thrombocy-
topenia, concerns about gastrointestinal tract absorption).
c This recommendation does not apply to patients who require
anticoagulation to prevent thrombosis of extracorporeal
circuits such as those on extracorporeal membrane oxygena-
tion (ECMO) or continuous renal-replacement therapy (CRRT).
Recommendation 2. The ASH guideline panel suggests using
prophylactic-intensity over intermediate-intensity or therapeutic-intensity
anticoagulation for patients with COVID-19–related acute illness who
do not have suspected or confirmed VTE (conditional recommendation
based on very low certainty in the evidence about effects Å◯◯◯).
Remarks:
c Between the time this recommendation was published online (27
October 2020) and when it was published in Blood Advances, a
press release (https://www.nih.gov/news-events/news-releases/
full-dose-blood-thinners-decreased-need-life-support-improved-
outcome-hospitalized-covid-19-patients) describing the resu-
lts of a planned interim analysis of 3 randomized controlled
trials, REMAP-CAP, ACTIV-4, and ATTACC (NCT 02735707,
04505774, and 04372589, respectively), was issued. In these
trials, therapeutic-intensity anticoagulation was compared with
prophylactic-intensity anticoagulation in moderately ill hospital-
ized patients with COVID-19. The ASH guideline panel plans to
update this recommendation when the full results of REMAP-
CAP, ACTIV-4, and ATTACC become available. Clinicians
should weigh the potential benefits and harms based on the
most up-to-date available evidence in caring for their patients.
c Patients with COVID-19–related acute illness are defined as
those with clinical features that would typically result in
admission to a medicine inpatient ward without requirement
for advanced clinical support. Examples include patients with
dyspnea or mild to moderate hypoxia.
c An individualized assessment of the patient’s risk of thrombosis and
bleeding is important when deciding on anticoagulation intensity.
Risk-assessment models to estimate thrombotic and bleeding risk
in hospitalized patients are available, but they have not been
validated for patients with COVID-19. The panel acknowledges that
higher-intensity anticoagulation may be preferred for patients
judged to be at high thrombotic risk and low bleeding risk.
c At present, there is no direct high-certainty evidence comparing
different types of anticoagulants. The selection of a specific agent
(eg, low-molecular-weight heparin, unfractionated heparin, etc)
may be based on availability, resources required, familiarity, and
the aim of minimizing PPE use or staff exposure to COVID-
19–infected patients as well as patient-specific factors (eg,
renal function, history of heparin-induced thrombocytopenia,
concerns about gastrointestinal tract absorption).
Values and preferences
The guideline panel identified all-cause mortality, pulmonary
embolism (PE), deep vein thrombosis (DVT), and major bleeding
as critical outcomes, and placed a high value on avoiding these
outcomes with the interventions assessed. Multiple organ failure,
severe ischemic stroke, intracranial hemorrhage, invasive ventila-
tion, limb amputation, ICU/critical care unit (CCU) hospitalization, and
ST-elevation myocardial infarction were also judged to be critical
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outcomes but could not be assessed as there was no direct evidence
available. Panel members noted that there was possible uncertainty
and variability in the relative value that patients place on avoiding
major bleeding events compared with reducing thrombotic events.
Explanations and other considerations
These recommendations take into consideration cost, impact
on equity, acceptability, and feasibility. Although the cost of
intermediate- or therapeutic-intensity anticoagulation may be
higher than prophylactic-intensity anticoagulation, the panel
determined that the incremental cost of higher-intensity anti-
coagulation was negligible relative to the total costs of care for
hospitalized patients with COVID-19. ASH will develop tools
to facilitate the dissemination and implementation of the recom-
mendations including a pocket guide, mobile application, and
educational slide set.
Introduction
Aims of these guidelines and specific objectives
The purpose of these guidelines is to provide evidence-based
recommendations on the use of anticoagulation for patients with
COVID-19–related acute and critical illness who do not have
suspected or confirmed VTE. Through improved provider and patient
education of the available evidence and evidence-based recommen-
dations, these guidelines aim to provide clinical decision support for
shared decision-making with the goal of improved patient outcomes.
The target audience includes patients, hematologists, general
practitioners, hospitalists, internists, intensivists, other clinicians,
and decision-makers. Policy makers interested in these guidelines
include those involved in developing local, national, or international
plans aiming to prevent the development of VTE for patients with
COVID-19–related illness. This document may also serve as the
basis for adaptation by local, regional, or national guideline panels.
Description of the health problem
The COVID-19 pandemic has had a significant public health
impact. As of 28 October 2020, over 44 million cases and 1.1 million
deaths had been attributed to COVID-19–related illness globally.16
COVID-19–related respiratory illness has led to a substantial burden
of hospitalization. It is estimated that 5% to 20% of infected patients
require hospital admission, of whom 5% to 15% may develop critical
illness requiring intensive care support.17-19
VTE has emerged as an important complication for patients
hospitalized with COVID-19. Early reports documented high rates
of VTE (and, in particular, PE) for patients hospitalized with COVID-
19–related acute illness and critical illness despite pharmacological
thromboprophylaxis.20-25 In addition, arterial thrombotic complica-
tions including stroke have been noted in early case series.26,27
Microvascular thrombosis, which may involve the pulmonary
vasculature and other organs, has been reported in autopsy
studies, although its impact on the development of respiratory and
multiorgan failure remains unclear.28,29 Imaging studies have con-
firmed that the radiological appearance of PE differs in COVID-19
compared with non–COVID-19 patients, with more peripheral
localization of thrombi and generally lower clot burden.30,31 These
observations may support the hypothesis that for patients with
COVID-19, PE may result from in situ immunothrombosis rather than
from embolization from lower-extremity DVT. In this report, the term
PE is used to collectively refer to both embolus and in situ thrombus
of the pulmonary arteries.
The mechanisms of hypercoagulability in COVID-19 have yet to be
fully elucidated. Characteristic hemostatic abnormalities including
elevations in factor VIII, von Willebrand factor, fibrinogen, and
D-dimer concentration have been described.2,4,32 Endotheliopathy,
due either to direct viral invasion or immune-mediated endothelial
injury, may also play an important role.33,34
The optimal thromboprophylaxis strategy for patients hospitalized
with COVID-19–related illness remains uncertain.21-23,35 Several
laboratory predictors of VTE in hospitalized patients with COVID-19
have been reported including elevated D-dimer, C-reactive protein,
erythrocyte sedimentation rate, and platelet count.36,37 In addition,
clinical risk factors for VTE in COVID-19 have been identified
including the development of acute respiratory distress syndrome20
and older age.23 However, it remains unclear whether these or other
parameters should be used to stratify patients for risk of thrombotic
complications, or influence decisions about thromboprophylaxis
intensity. Although COVID-19–associated coagulopathy appears to
be marked primarily by thrombotic complications, patients may develop
major bleeding complications on anticoagulation therapy, which can
impact the safety of intensified thromboprophylaxis regimens.36,38
Description of the target populations
For this guideline, the panel separately considered 2 groups of
patients: those with COVID-19–related acute illness and critical
illness. These patient populations are typically defined by the setting
of hospital admission (medical ward and ICU/CCU, respectively) as
an indication of illness severity.39 However, the panel acknowl-
edged that during the COVID-19 pandemic, such patients may not
be admitted to the hospital or ICU owing to limitations in hospital
capacity and health care resources, despite meeting traditional
criteria for provision of care in these settings. The panel also
acknowledged that criteria for admission to the hospital or ICU/
CCU may vary by institution or region. Therefore, the panel defined
COVID-19–related acute illness and critical illness based on clinical
features rather than the type of unit to which the patient was
admitted (Table 2).39-43
The panel defined patients with COVID-19–related critical illness
as those suffering from an immediately life-threatening condition
who would typically be admitted to an ICU/CCU for advanced
clinical support.39 Examples include patients requiring hemodynamic
support, ventilatory support including mechanical ventilation, and
renal-replacement therapy.42 Patients with critical illness in the
absence of COVID-19 may be at increased thrombotic risk due to a
variety of risk factors including advanced age, immobility, infection,
central venous catheterization, and other comorbid illness.43
The panel defined patients with COVID-19–related acute illness
as those with clinical features that would typically result in admission
to a medicine inpatient ward without requirement for advanced
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clinical support. Examples include patients with dyspnea or mild
to moderate hypoxia. Patients with acute illness in the absence of
COVID-19 are at increased risk for VTE due to a variety of risk
factors including reduced mobility, age, organ dysfunction, and
other comorbid illness.40,41
Risk-assessment models have been developed to assess bleeding
and thrombosis risk in hospitalized medical patients, but these tools
remain to be validated and have not been well studied for patients
hospitalized with COVID-19.40,44-46
Methods
We developed and will maintain these “living” guideline recommen-
dations in 2 phases. During the first phase, we used methodology
for guideline development consistent with the ASH guidelines
for management of VTE, but with a condensed timeline.47 This was
a rapid guideline-development process, with systematic review
searches being conducted on 19 July and 19 August 2020, followed
by the drafting of recommendations on 29 September 2020. Panel
and Methods team members also suggested additional important
eligible studies until 29 September 2020. During the second phase,
using a living guideline approach (supplemental File 1), we aim to
provide updates using the living recommendations approach that we
previously conceptualized based on living systematic reviews (https://
community.cochrane.org/sites/default/files/uploads/inline-files/
Transform/201912_LSR_Revised_Guidance.pdf).48-51
To assess the certainty in the body of evidence and develop
recommendations, we followed the GRADE approach.9-12,15,48,52
The overall guideline-development process, including funding of the
work, panel formation, management of conflicts of interest, internal and
external review, and organizational approval, was guided by ASH
policies and procedures derived from theGIN-McMaster Guideline De-
velopment Checklist (http://cebgrade.mcmaster.ca/guidecheck.html)53
intended to meet recommendations for trustworthy guidelines by the
Institute of Medicine and GIN.6-8 We report the guideline following
the RIGHT checklist (supplemental File 2).54
Organization, panel composition, planning,
and coordination
The work of this panel was coordinated by ASH and the McMaster
University GRADE Center (funded by ASH under a paid agree-
ment). Project oversight was provided by the ASH Guideline
Oversight Subcommittee, which reported to the ASH Committee
on Quality. ASH vetted and appointed individuals to the guideline
panel. The McMaster University GRADE Centre vetted and
retained researchers to conduct systematic reviews of evidence
and coordinate the guideline-development process including the
use of the GRADE approach. The membership of the panels and
the systematic review team are described in supplemental File 3.
The panel included adult and pediatric hematologists, internists,
intensivists, an infectious disease specialist, a nephrologist, and an
anticoagulation pharmacist with expertise on the guideline topic,
and 3 patient representatives. The panel was chaired by 1 clinical
co-chair (A.C.) and 2 guideline methodology co-chairs (H.J.S.,
R.A.M.).
In addition to synthesizing evidence systematically, the McMaster
University GRADE Centre supported the guideline-development
process, including determining methods, preparing meeting mate-
rials, and facilitating panel discussions. The panel’s work was done
using Web-based tools (www.surveymonkey.com and www.grade-
pro.org) and online meetings.
In the living phase, we will apply and enhance these processes of
guideline development in the following ways. We aim to retain the
composition of panel members throughout the development of the
living recommendations unless conflicts of interest emerge that
could lead to exclusion of panel members or members decide to
leave the panel for other reasons. All panel members will be
apprised of potential changes to the evidence and engaged for
reassessment of new evidence. If dictated by the emergence of new
evidence, they will support the updating of living recommendations
based on explicit criteria.
Guideline funding and management of conflicts
of interest
Development of these guidelines was wholly funded by ASH, a
nonprofit medical specialty society that represents hematologists.
Direct funding by for-profit companies was not accepted. ASH staff
supported panel appointments and coordinated meetings but had
no role in choosing the guideline questions or determining the
recommendations.
Through funding by ASH to the McMaster University GRADE
Centre, some of the researchers who contributed to the systematic
evidence reviews received salary or grant support. Other researchers
participated to fulfill requirements of an academic degree or program.
The guideline panel received no payments or reimbursements from
ASH for their work on these guidelines.
Conflicts of interest of all participants were managed according
to ASH policies based on recommendations of the Institute of
Medicine55 and GIN.7 Participants disclosed all financial and
nonfinancial interests relevant to the guideline topic. ASH staff
and the ASH Guideline Oversight Subcommittee reviewed the
disclosures and composed the guideline panel to include a diversity
of expertise and perspectives and to avoid a majority of the panel
having the same or similar conflicts. Greatest attention was given
to conflicts from direct financial interests in for-profit companies
that could be affected by the guidelines. During the guideline-
development process, all members of the guideline panel and all
members of the systematic review team avoided direct financial
interests in for-profit health care companies more than $5000 per
year regardless of relevance to the guideline topic.
Supplemental File 4 provides “Participant Information Forms” for
all panel members, detailing financial and nonfinancial interests,
as well as the ASH conflict-of-interest policies agreed to by each
Table 2. Definitions of target populations
Target population Definition
Critically ill • Patients with COVID-19 who develop respiratory or
cardiovascular failure normally requiring advanced clinical
support in the ICU or CCU, but could include admission to
another department if the ICU/CCU was over capacity
• ICU/CCU capacity and admission criteria could vary according to
the specific setting
Acutely ill • Patients with COVID-19 who require hospital admission without
advanced clinical support (ie, not to the ICU/CCU), but could
include treatment in other settings if the hospital was over
capacity
• Hospital capacity and admission criteria could vary according to
the specific setting
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individual. Supplemental File 5 provides the complete Participant
Information Forms of researchers on the systematic review team
who contributed to these guidelines.
Formulating specific clinical questions and
determining outcomes of interest
The panel used the GRADEpro Guideline Development Tool
(www.gradepro.org)56 and SurveyMonkey (www.surveymonkey.com)
to brainstorm and then prioritize the questions. The aim was to
develop a “small informative recommendation unit” that would create
focused clinical questions that could be answered in a timely manner,
and then clearly and feasibly implemented by clinicians.57 The
prioritized questions were:
1. For patients with COVID-19–related critical illness who do
not have confirmed or suspected VTE, should we use direct
oral anticoagulants, low-molecular-weight heparin, unfrac-
tionated heparin, fondaparinux, argatroban, or bivalirudin at
intermediate intensity or therapeutic intensity vs prophylactic
intensity?
2. For patients with COVID-19–related acute illness who do not
have confirmed or suspected VTE, should we use direct oral
anticoagulants, low-molecular-weight heparin, unfractionated
heparin, fondaparinux, argatroban, or bivalirudin at intermediate
intensity or therapeutic intensity vs prophylactic intensity?
Table 3. Classification of anticoagulant regimens by intensity
Regimen
Prophylactic*
Apixaban 2.5 mg, PO BID (with intent for VTE prophylaxis)
Bemiparin 3500 U, SC OD
Betrixaban 80 mg, PO OD
Betrixaban 160 mg, PO OD
Dabigatran 220 mg, PO OD
Dalteparin 5000 U, SC OD
Enoxaparin 30 mg (3000 U), SC OD (for GFR 15-30)
Enoxaparin 30 mg (3000 U), SC BID (for BMI $40 kg/m2)
Enoxaparin 40 mg (4000 U), SC OD
Enoxaparin 40 mg (4000 U), SC BID (for BMI $40 kg/m2)
Fondaparinux 2.5 mg, SC OD
Unfractionated heparin 5000 U, SC BID
Unfractionated heparin 5000 U, SC TID
Unfractionated heparin 7500 U, SC BID (for BMI $40 kg/m2)
Nadroparin 2850 U, SC q24h (post-op general surgery)
Nadroparin 5700 U, SC q24h (high-risk medical patients .70 kg)
Nadroparin 3800 U, SC q24h (high-risk medical patients #70 kg or post-op hip
replacement surgery)
Rivaroxaban 10 mg, PO OD
Tinzaparin 3500 U, SC OD
Tinzaparin 4500 U, SC OD
Tinzaparin 75 U/kg, SC OD
Intermediate*
Enoxaparin 0.5 mg/kg (50 U/kg), SC BID (if CrCl .30 mL/min)
Enoxaparin 0.5 mg/kg (50 U/kg), SC OD (if CrCl ,30 mL/min)
Enoxaparin 30 mg (3000 U), SC BID (for BMI ,40 kg/m2)
Enoxaparin 40 mg (4000 U), SC BID (for CrCl .30 mL/min and BMI ,40 kg/m2)
Enoxaparin 60 mg (6000 U), SC BID (for CrCl .30 mL/min and BMI .40 kg/m2)
Unfractionated heparin 7500 U, SC TID
Dalteparin 5000 U, SC BID
Therapeutic*
Acenocoumarol, PO (target INR 2.0-3.0 or greater)
Apixaban 5 mg, PO BID
Apixaban 10 mg, PO BID
Argatroban, IV to target aPTT therapeutic range as per institutional guidelines
Bemiparin 5000 U, SC OD (if weight #50 kg and CrCl .30 mL/min)
Bemiparin 7500 U, SC OD (if weight 50-70 kg and CrCl .30 mL/min)
Bemiparin 10000 U, SC OD (if weight 70-100 kg and CrCl .30 mL/min)
Bemiparin 115 U/kg, SC OD (if weight .100 kg and CrCl .30 mL/min)
Bivalirudin, IV to target aPTT therapeutic range as per institutional guidelines
Dabigatran 75 mg, PO BID (if CrCl 15-30 mL/min)
Dabigatran 110 mg, PO BID (AF: age $80 y, or .75 y and 1 or more risk factors for
bleeding)
Dabigatran 150 mg, PO BID (if CrCl .30 mL/min)
Dalteparin 100 U/kg, SC BID
Dalteparin 150 U/kg, SC OD
Dalteparin 200 U/kg, SC OD
Edoxaban 30 mg, PO OD (#60 kg, CrCl 15-50 mL/min)
Table 3. (continued)
Regimen
Edoxaban 60 mg, PO OD (weight $60 kg and CrCl .50 mL/min)
Enoxaparin 0.8 mg/kg, SC BID (for BMI .40 and CrCl .30 mL/min)
Enoxaparin 1 mg/kg (100 U/kg), SC BID (for CrCl .30 mL/min)
Enoxaparin 1.5 mg/kg (150 U/kg), SC OD (for CrCl .30 mL/min)
Enoxaparin 1 mg/kg (100 U/kg), SC OD (for CrCl ,30 mL/min)
Tinzaparin 175 U/kg, SC OD
Fluindione, PO (target INR 2.0-3.0 or greater)
Fondaparinux 5 mg, SC OD (if weight ,50 and CrCl .50 mL/min
Fondaparinux 5 mg, SC OD (if weight 50-100 kg and CrCl 30-50 mL/min)
Fondaparinux 7.5 mg, SC OD (if weight 50-100 kg and CrCl .50 mL/min
Fondaparinux 7.5 mg, SC OD (if weight .100 kg and CrCl 30-50 mL/min)
Fondaparinux 10 mg, SC OD (if weight .100 kg and CrCl .30 mL/min)
Unfractionated heparin, IV to target aPTT therapeutic range as per institutional guidelines
or anti-Xa activity 0.3-0.7 IU/mL
Unfractionated heparin 250 U/kg, SC q12h
Nadroparin 86 U/kg, SC q12h (for acute coronary syndrome)
Nadroparin 171 U/kg, q24h (for DVT treatment)
Phenprocoumon, PO (target INR 2.0-3.0 or greater)
Rivaroxaban 15 mg, PO BID
Rivaroxaban 15 mg, PO OD (for GFR 15-50 in AF patients)
Rivaroxaban 20 mg, PO OD
Warfarin, PO (target INR 2.0-3.0 or greater)
AF, atrial fibrillation; aPTT, activated partial thromboplastin time; BID, twice daily; BMI,
body mass index; CrCl, creatinine clearance; GFR, glomerular filtration rate; INR,
international normalized ratio; OD, once a day; PO, oral; post-op, postoperative; q12h,
every 12 hours; q24h, every 24 hours; SC, subcutaneous; TID, 3 times a day.
*Intensity of anticoagulation.

















L user on 07 M
arch 2021
Definitions
We defined COVID-19 according to theWorld Health Organization
(WHO) criteria (https://www.who.int/emergencies/diseases/novel-
coronavirus-2019/technical-guidance/laboratory-guidance) includ-
ing suspected, probable, and confirmed cases. All included studies
enrolled, exclusively or largely, laboratory-confirmed COVID-19
patients.
We used the following definition for critical illness related to
COVID-19 (Table 2): respiratory or cardiovascular failure normally
requiring advanced clinical support in the ICU or CCU, but could
include admission to another department if the ICU/CCU was over
capacity. ICU/CCU capacity and admission criteria could vary
according to the specific setting.
We applied the following definition to acute illness related to
COVID-19 (Table 2): normally requiring hospital admission
without advanced clinical support (ie, not to the ICU/CCU), but
could include treatment in other clinical settings if the hospital was
over capacity. Hospital capacity and admission criteria could vary
according to the specific setting. Some studies reported on all
hospitalized COVID-19 patients and had ,20% in the ICU/CCU
without separating their outcomes, and such populations were
labeled as acutely ill.
A guideline panel working group predefined prophylactic-, in-
termediate-, and therapeutic-intensity anticoagulation, and the
overall panel approved these definitions (Table 3). Interventions
reported in included studies were categorized according to these
definitions. Studies not providing sufficient details to categorize the
intensities according to our definitions were labeled according to
the authors’ definition of the intensity.
The panel selected outcomes of interest for each prioritized question
a priori, following the approach described in detail elsewhere.47
In brief, we used the outcomes that the ASH management of
VTE guideline panels prioritized as our initial candidate outcomes
using health outcome descriptors (https://ms.gradepro.org).39,58-64
We then asked for additional outcomes that may be important or
critical for decision-making in COVID-19–related illness. The
panel considered the following outcomes as critical for clinical
decision-making: all-cause mortality, PE, DVT of the upper leg,
VTE (including DVT or PE), major bleeding, multiple organ failure,
severe ischemic stroke, intracranial hemorrhage, invasive venti-
lation, limb amputation, ICU hospitalization, and ST-elevation
myocardial infarction.
Typically, included studies reported venous thromboembolic out-
comes as any PE, any DVT, or any VTE, without further specification.
Some studies did not distinguish asymptomatic thromboembolic
events that were detected by the routine performance of sensitive
screening studies for VTE from symptomatic thromboembolic events
where patients developed overt signs or symptoms that were
subsequently confirmed by objective testing to be associated with
VTE. Reporting of symptomatic thromboembolic events was in-
consistent across studies.
Where available, we included evidence from studies that reported
symptomatic thromboembolic events. As the ratio of screening-
detected and symptomatic thromboembolic events is not yet
established in COVID-19 patients, we made no assumptions about
the distribution of asymptomatic vs symptomatic outcomes.
We used evidence for major bleeding as labeled by the study
authors, as outcome definitions were not always provided.
The duration of follow-up for the prioritized outcomes was captured,
and outcome rates at 14- to 35-day follow-up were used when data
were available. The evidence for prioritized outcomes other than mortality,
VTE, and major bleeding, and details on their reported definitions,
will be provided in the living phase for these recommendations.
We do not expect changes to the questions, outcomes, and
definitions during the living phase, but will reconsider them if
deemed necessary by the panel based on new insights.
Evidence review and development
of recommendations
For each guideline question, the McMaster University GRADE
Centre prepared a GRADE “Evidence-to-Decision” (EtD) frame-
work, using the GRADEpro Guideline Development Tool
(www.gradepro.org).9,10,52 The EtD table summarized the results
of systematic reviews of the literature that were updated or performed
for this guideline. The EtD table addressed the baseline risk for critical
outcomes, effects of interventions, resource utilization (cost and
cost-effectiveness), values and preferences (relative importance of
outcomes), equity, acceptability, and feasibility. The guideline panel
reviewed draft EtD tables before, during, and after the guideline
panel meeting, made suggestions for corrections, and identified
missing evidence. To ensure that we did not miss recent studies in
preparation for voting on the recommendations, we asked panel
members to suggest any studies that may have been published
after the most recent systematic review search dates (19 July
2020 for the baseline risk review and 19 August 2020 for review
of the anticoagulation-intensity effect) and fulfilled the inclusion
criteria for the individual questions (see supplemental Files 6 and
7 for the search strategies per targeted database).
Under the direction of the McMaster University GRADE Centre,
researchers followed the general methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (handbook.co-
chrane.org) and Cochrane guidance for conducting living system-
atic reviews of intervention effects49-51,65 (see supplemental Files 8
and 9 for detailed protocols for the reviews of the baseline risk
and anticoagulation-intensity effect). For new reviews, risk of bias
was assessed at the health outcome level using the Cochrane
Collaboration’s risk-of-bias tool for randomized trials of interven-
tions, or ROBINS-I for nonrandomized studies of interventions, or
the Newcastle-Ottawa Scale for case-control studies with anti-
coagulation intensity as exposure. In addition to conducting systematic
reviews of intervention effects, the researchers searched for
evidence related to baseline risks, values, preferences, and costs,
and summarized findings within the EtD frameworks.9,10,52 Sub-
sequently, we assessed the certainty in the body of evidence (also
known as quality of the evidence or confidence in the estimated
effects) for each effect estimate of the outcomes of interest
following the GRADE approach based on the following domains:
risk of bias, precision, consistency and magnitude of the estimates
of effects, directness of the evidence, risk of publication bias,
presence of large effects, dose-response relationship, and an
assessment of the effect of residual, opposing confounding. The
certainty was categorized into 4 levels ranging from very low to
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high.11,15,48 Within this report, these categories are represented by
symbols, as follows:
ÅÅÅÅ High certainty in the evidence about effects
ÅÅÅ◯ Moderate certainty in the evidence about effects
ÅÅ◯◯ Low certainty in the evidence about effects
Å◯◯◯ Very low certainty in the evidence about effects
Interested readers may find more explanation about the GRADE
approach to assessing and rating certainty in a body of evidence in
other publications.11,15,48
We conducted new systematic reviews to establish the base
recommendation in our first phase. We will use existing systematic
reviews to supplement our ongoing living reviews. The panel
decided not to use indirect evidence from non–COVID-19 patients
for baseline risk or the effects of interventions. However, as we
identified no COVID-19–specific evidence for other EtD do-
mains including patients’ values and preferences, resource use,
acceptability, and feasibility, we used the evidence from the ASH
guidelines on management of VTE regarding prophylaxis for
hospitalized medical patients for these EtD criteria.39
Using weekly conference calls, online communication, and GRA-
DEpro software, the panel developed clinical recommendations
based on the evidence summarized in the EtD tables. For each
recommendation, the panel took a population perspective and
came to consensus on the following: the certainty in the evidence,
the balance of benefits and harms of the compared management
options, and the assumptions about the values and preferences
associated with the decision. The guideline panel also explicitly took
into account the extent of resource use associated with alternative
management options.
The panel agreed on the recommendations (including direction and
strength), remarks, and qualifications by consensus based on the
balance of all desirable and undesirable consequences. With
regard to arriving at recommendations, panel members reviewed
the identified evidence, which was synthesized and provided to
them along with the individual studies. Multiple rounds of feedback
on this research evidence was sought both electronically and during
virtual panel meetings. Anonymous prevoting on individual criteria of
the EtD was conducted to identify areas requiring more discussion
(eg, understanding a study’s intervention effects). In using the EtD
frameworks, voting was only to be used if consensus did not
emerge on a criterion or for the recommendation and final
dissents were to be noted. Because consensus was achieved on
all judgments, voting was not necessary and no dissents were reg-
istered. The final guidelines, including recommendations, were
reviewed and approved by all panel members and all meetings were
video-recorded to document the process.
In the living phase, we will update systematic reviews on a monthly
basis and, when meeting explicit criteria, conduct new meta-
analyses to incorporate changes (see supplemental Files 1 and
9 for details).48 We will deploy machine learning to facilitate
screening the large volume of research evidence and conduct
network meta-analysis if possible. We will inform the “living”
guideline panel about changes in the evidence and will determine
whether the published recommendations will need to be reas-
sessed, according to explicit criteria. These criteria include:
c New information on a critical outcome that previously had no
included studies
c Changes to the magnitude of the absolute effect for at least 1
critical outcome
c Changes to the certainty in the evidence for absolute effect for
at least 1 critical outcome (eg, from very low/low to moderate/
high)
c Potential change in the judgments regarding any other criteria
(costs, feasibility, acceptability, equity) that has an important
bearing on the recommendation
We will develop the living recommendations using the GRADEpro
EtD to make judgments about all evidence, following the same
processes we used for our original recommendations. After
reassessment of a recommendation, whether the recommendation
changes or not, we will highlight in the EtDs when the recommen-
dation was reassessed and the reasons for reassessment, and we
will describe the rationale for any changes or the lack of changes.
Interpretation of strong and
conditional recommendations
The recommendations are labeled as either “strong” or “conditional”
according to the GRADE approach. The words “the guideline panel
recommends” are used for strong recommendations, and “the
guideline panel suggests” for conditional recommendations. Table 4
provides GRADE’s interpretation of strong and conditional recom-
mendations by patients, clinicians, health care policy makers, and
researchers.38
Document review
Draft recommendations were reviewed by all members of the panel,
revised, and then made available online on 8 October 2020 for
external review by stakeholders including allied organizations, other
medical professionals, patients, and the public. Two individuals or
organizations submitted comments. The document was revised to
address pertinent comments, but no changes were made to
recommendations. On 26 October 2020, the ASH Guideline
Oversight Subcommittee and the ASH Committee on Quality
approved that the defined guideline-development process was
followed, and on 2 November 2020 the officers of the ASH
Executive Committee approved submission of the guidelines for
publication under the imprimatur of ASH. The guidelines were then
subjected to peer review by Blood Advances.
How to use these guidelines
ASH guidelines are primarily intended to help clinicians make decisions
about diagnostic and treatment alternatives. Other purposes are to
inform policy, education, and advocacy, and to state future research
needs. They may also be used by patients. These guidelines are not
intended to serve or be construed as a standard of care. Clinicians
must make decisions on the basis of the clinical presentation of
each individual patient, ideally through a shared process that
considers the patient’s values and preferences with respect to the
anticipated outcomes of the chosen option. Decisions may be
constrained by the realities of a specific clinical setting and local
resources, including but not limited to institutional policies, time
limitations, or availability of treatments. These guidelines may not
include all appropriate methods of care for the clinical scenarios
described. As science advances and new evidence becomes
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available, recommendations may become outdated. Following
these guidelines cannot guarantee successful outcomes. ASH
does not warrant or guarantee any products described in these
guidelines.
Statements about the underlying values and preferences as well as
qualifying remarks accompanying each recommendation are its
integral parts and serve to facilitate more accurate interpretation.
They should never be omitted when quoting or translating
recommendations from these guidelines. The use of these guide-
lines is also facilitated by the links to the EtD frameworks and
interactive summary-of-findings tables in each section. The ASH
users’ guide to recommendations provides additional insights into
how to use the recommendations.66 Guideline users need to be
aware that the guideline recommendations may change in the living
phase as new evidence becomes available. ASH will publish and
alert readers to such updates, but guideline users are responsible
for being informed about changes.
Recommendations
Patients with COVID-19–related critical illness
Should direct oral anticoagulants, low-molecular-weight heparin,
unfractionated heparin, fondaparinux, argatroban, or bivalirudin at
intermediate intensity or therapeutic intensity vs prophylactic intensity
be used for patients with COVID-19–related critical illness who do
not have suspected or confirmed VTE?
Recommendation 1
The ASH guideline panel suggests using prophylactic-intensity
over intermediate-intensity or therapeutic-intensity anticoagulation
for patients with COVID-19–related critical illness who do
not have suspected or confirmed VTE (conditional recom-
mendation based on very low certainty in the evidence about
effects Å◯◯◯).
Remarks:
c Between the time this recommendation was published
online (27 October 2020) and when it was published in
Blood Advances, a press release (https://www.nih.gov/
news-events/news-releases/nih-activ-trial-blood-thinners-
pauses-enrollment-critically-ill-covid-19-patients) de-
scribing the results of a planned interim analysis of 3
randomized controlled trials, REMAP-CAP, ACTIV-4, and
ATTACC (NCT 02735707, 04505774, and 04372589,
respectively), was issued. In these trials, therapeutic-
intensity anticoagulation was compared with pro-
phylactic-intensity anticoagulation for patients with
COVID-19–related critical illness. The ASH guideline
panel plans to update this recommendation when the
full results of REMAP-CAP, ACTIV-4, and ATTACC
become available. Clinicians should weigh the poten-
tial benefits and harms based on the most up-to-date
available evidence in caring for their patients.
c Patients with COVID-19–related critical illness are
defined as those suffering from an immediately life-
threatening condition who would typically be admit-
ted to an ICU. Examples include patients requiring
hemodynamic support, ventilatory support, and re-
nal-replacement therapy.
c An individualized assessment of the patient’s risk of
thrombosis and bleeding is important when deciding on
anticoagulation intensity. Risk-assessment models to
estimate thrombotic and bleeding risk in hospitalized
patients are available, but they have not been validated
for patients with COVID-19. The panel acknowledges
that higher-intensity anticoagulation may be preferred for
patients judged to be at high thrombotic risk and low
bleeding risk.
c At present, there is no direct high-certainty evidence
comparing different types of anticoagulants. The selec-
tion of a specific agent (eg, low-molecular-weight
heparin, unfractionated heparin, etc) may be based on
availability, resources required, familiarity, and the aim
of minimizing PPE use or staff exposure to COVID-
19–infected patients as well as patient-specific fac-
tors (eg, renal function, history of heparin-induced
thrombocytopenia, concerns about gastrointestinal tract
absorption).
c This recommendation does not apply to patients who
require anticoagulation to prevent thrombosis of extra-
corporeal circuits such as those on ECMO or CRRT.
Summary of the evidence. For all outcomes, we rated the
certainty in the evidence as very low owing to serious or very serious
risk of bias and imprecision of the estimates (see evidence profile
and EtD online at: https://guidelines.ash.gradepro.org/profile/
3CQ7J0SWt58). We found no systematic reviews that addressed
this question. Altogether, there were 5 observational studies that
provided evidence related to this question.25,67-70 All studies exclusively
or largely included patients with laboratory-confirmed COVID-19 who
were categorized as critically ill or admitted to the ICU. Supplemental
File 10 presents the characteristics of all included studies.
One study reported the effect of therapeutic-intensity anticoagula-
tion on all-cause mortality and major bleeding,67 1 study reported
the effect of intermediate-intensity anticoagulation on the develop-
ment of PE,70 1 study reported the effect of intermediate-intensity
anticoagulation on the development of DVT,69 and 2 studies reported
the effect of therapeutic-intensity anticoagulation on the development
of VTE (either DVT or PE).25,68 No studies reported the effect of
therapeutic- or intermediate-intensity anticoagulation on multiple
organ failure, severe ischemic stroke, intracranial hemorrhage, invasive
ventilation, limb amputation, or ST-elevation myocardial infarction.
Benefits. Therapeutic-intensity anticoagulation may reduce the
risk of all-cause mortality but the evidence is very uncertain (adjusted
odds ratio [OR], 0.73; 95% confidence interval [CI], 0.33-1.76); this
corresponds to 52 fewer (from 143 fewer to 116 more) deaths per
1000 patients (very low certainty).67 Intermediate-intensity anticoagu-
lation may reduce the risk of PE but the evidence is very uncertain
(adjusted OR, 0.09; 95%CI, 0.02-0.57); this corresponds to 88 fewer
(from 96 to 40 fewer) PEs per 1000 patients (very low certainty).70
Intermediate-intensity anticoagulation may reduce the risk of DVT but
the evidence is very uncertain (OR, 0.35; 95% CI, 0.06-2.02); this
corresponds to 66 fewer (from 99 fewer to 87 more) DVTs per 1000
patients (very low certainty).69 Studies assessing the effect of
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therapeutic-intensity anticoagulation on VTE found that it may result in a
small difference but the evidence is very uncertain (pooled OR, 0.87;
95%CI, 0.45-1.67); this corresponds to 15 fewer (from 67 fewer to 70
more) VTE per 1000 patients (very low certainty).25,68
Harms and burden. Therapeutic-intensity anticoagulation may
increase the risk of major bleeding but the direct evidence in critically
ill COVID-19 patients is uncertain (OR, 3.84; 95% CI, 1.44-10.21);
this corresponds to 176 more (from 33 to 400 more) major bleeding
events per 1000 patients (very low certainty due to risk of bias and
imprecision).67 However, the panel also considered a plethora of
indirect evidence in non–COVID-19 critically ill patients demonstrat-
ing a dose-dependent effect of anticoagulation on bleeding risk.71-74
Other EtD criteria and considerations. The guideline panel
noted that there was possible uncertainty and variability in the relative
value patients place on reducing thrombotic events compared with
avoiding major bleeding events. The panel agreed that the use of
intermediate-intensity or therapeutic-intensity anticoagulation would be
acceptable to patients and health care providers. However, given the
very low certainty in the evidence there may be regional variation in the
acceptability of higher-intensity anticoagulation, particularly in regions
where baseline VTE risk may be lower (eg, Asian populations).75,76
The panel recognized that COVID-19 disproportionately affects
certain racial and ethnic groups, including Black and Hispanic
individuals. However, the use of intermediate-intensity or therapeutic-
intensity anticoagulation was judged not to have a differential
impact on health equity relative to the use of prophylactic-intensity
anticoagulation. Although higher-intensity anticoagulation would
result in a higher drug cost, the panel judged this difference to be
negligible relative to the total costs of providing critical care.
Conclusions for this recommendation. The panel judged
that there was very low–certainty evidence in the desirable and
undesirable effects of intermediate-intensity or therapeutic-intensity
anticoagulation for patients with COVID-19–related critical illness.
There was a suggestion of mortality benefit and reduction in VTE
with intermediate-intensity or therapeutic-intensity anticoagulation,
but this evidence was of very low certainty.
Meanwhile, there was less uncertainty in the potential undesirable
effects of intermediate-intensity or therapeutic-intensity anticoagulation
in increasing the risk of major bleeding complications. The panel
considered that there was higher-quality indirect evidence from
non–COVID-19 critically ill patients for a dose-dependent increase in
the risk of major bleeding with anticoagulation, although the magnitude
of this effect was uncertain in the COVID-19 population.71-74 Given that
there was very low certainty for benefit to offset the moderate risk of
major bleeding complications, the usual practice of prophylactic-
intensity anticoagulation, as used in critically ill non–COVID-19 patients,
was suggested.39
The panel, however, recognized the potential for benefit and noted
that an individualized decision is important for each patient based
on an assessment of thrombosis and bleeding risk. For patients judged
to be at high thrombotic risk and low bleeding risk, panel members
acknowledged that higher-intensity anticoagulation could be considered.
Dose adjustment of prophylactic-intensity anticoagulation for extremes of
body weight or renal impairment may also be considered.77-81
This recommendation does not apply to thrombotic complications
related to extracorporeal circuits. Although high rates of circuit-
related thrombosis during ECMO and CRRT have been reported for
patients with COVID-19, this outcome was not prioritized by the
guideline panel as part of its systematic review of the evidence.20
Patients with COVID-19–related acute illness
Should direct oral anticoagulants, low-molecular-weight heparin,
unfractionated heparin, fondaparinux, argatroban, or bivalirudin
at intermediate-intensity or therapeutic-intensity vs prophylactic-
intensity be used for patients with COVID-19–related acute illness
who do not have suspected or confirmed VTE?
Recommendation 2
The ASH guideline panel suggests using prophylactic-intensity
over intermediate-intensity or therapeutic-intensity anticoagulation
for patients with COVID-19–related acute illness who do not
Table 4. Interpretation of strong and conditional recommendations
Implications for Strong recommendation Conditional recommendation
Patients • Most individuals in this situation would want the recommended
course of action, and only a small proportion would not
• The majority of individuals in this situation would want the
suggested course of action, but many would not
• Decision aids may be useful in helping patients to make decisions
consistent with their individual risks, values, and preferences
Clinicians •Most individuals should follow the recommended course of action
• Formal decision aids are not likely to be needed to help individual
patients make decisions consistent with their values and
preferences
• Recognize that different choices will be appropriate for individual
patients and that you must help each patient arrive at a
management decision consistent with their values and
preferences
• Decision aids may be useful in helping individuals to make
decisions consistent with their individual risks, values, and
preferences
Policy makers • The recommendation can be adopted as policy in most situations
• Adherence to this recommendation according to the guideline
could be used as a quality criterion or performance indicator
• Policymaking will require substantial debate and involvement of
various stakeholders
• Performance measures should assess whether decision-making
is appropriate
Researchers • The recommendation is supported by credible research or other
convincing judgments that make additional research unlikely to
alter the recommendation
• On occasion, a strong recommendation is based on low or very
low certainty in the evidence
• In such instances, further research may provide important
information that alters the recommendations
• The recommendation is likely to be strengthened (for future
updates or adaptation) by additional research
• An evaluation of the conditions and criteria (and the related
judgments, research evidence, and additional considerations)
that determined the conditional (rather than strong)
recommendation will help identify possible research gaps
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have suspected or confirmed VTE (conditional recommendation
based on very low certainty in the evidence about effectsÅ◯◯◯).
Remarks:
c Between the time this recommendation was pub-
lished online (27 October 2020) and when it was
published in Blood Advances, a press release (https://
www.nih.gov/news-events/news-releases/full-dose-blood-
thinners-decreased-need-life-support-improved-outcome-
hospitalized-covid-19-patients) describing the results
of a planned interim analysis of 3 randomized controlled
trials, REMAP-CAP, ACTIV-4, and ATTACC (NCT
02735707, 04505774, and 04372589, respectively),
was issued. In these trials, therapeutic-intensity anti-
coagulation was compared with prophylactic-intensity
anticoagulation for moderately ill hospitalized patients
with COVID-19. The ASH guideline panel plans to
update this recommendation when the full results of
REMAP-CAP, ACTIV-4, and ATTACC become avail-
able. Clinicians should weigh the potential benefits
and harms based on the most up-to-date available
evidence in caring for their patients.
c Patients with COVID-19–related acute illness are defined
as those with clinical features that would typically result in
admission to a medicine inpatient ward without re-
quirement for advanced clinical support. Examples in-
clude patients with dyspnea or mild to moderate hypoxia.
c An individualized assessment of the patient’s risk of
thrombosis and bleeding is important when deciding on
anticoagulation intensity. Risk-assessment models to esti-
mate thrombotic and bleeding risk in hospitalized patients
are available, but they have not been validated for patients
with COVID-19. The panel acknowledges that higher-
intensity anticoagulation may be preferred for patients
judged to be at high thrombotic risk and low bleeding risk.
c At present, there is no direct high-certainty evidence
comparing different types of anticoagulants. The selection
of a specific agent (eg, low-molecular-weight heparin,
unfractionated heparin, etc) may be based on availability,
resources required, familiarity, and the aim of minimizing
PPE use or staff exposure to COVID-19–infected patients
as well as patient-specific factors (eg, renal function, history
of heparin-induced thrombocytopenia, concerns about
gastrointestinal tract absorption).
Summary of the evidence. For all outcomes, we rated the
certainty in the evidence as very low owing to serious or very serious
risk of bias and imprecision of the estimates (see evidence profile and
EtD online at: https://guidelines.ash.gradepro.org/profile/phJkOBz3-
JEQ). We found no systematic reviews that addressed this question.
Altogether, there were 5 observational studies that provided evidence
related to this question.69,70,82-84 Three studies exclusively or largely
included patients with laboratory-confirmed COVID-19 who were
categorized as severely or moderately ill or hospitalized in a ward
other than the ICU. Two studies included patients with laboratory-
confirmed COVID-19 who were categorized as critically ill or
admitted to the ICU, as no reliable evidence was identified for PE
and DVT in acutely ill patients. Supplemental File 11 presents the
characteristics of all included studies.
One study reported the effect of therapeutic-intensity anticoagulation
on all-cause mortality,84 1 study reported the effect of intermediate-
intensity anticoagulation on the development of PE in critically ill
patients,70 1 study reported the effect of intermediate-intensity
anticoagulation on the development of DVT in critically ill patients,69
and 2 studies reported the effect of therapeutic-intensity anti-
coagulation on major bleeding.82,83 No studies reported the effect
of therapeutic- or intermediate-intensity anticoagulation on multi-
ple organ failure, severe ischemic stroke, intracranial hemorrhage,
invasive ventilation, limb amputation, or ST-elevation myocardial
infarction.
Benefits. Therapeutic-intensity anticoagulation may reduce the
risk of all-cause mortality but the evidence is very uncertain
(adjusted OR, 0.86; 95% CI, 0.73-1.02); this corresponds to 19
fewer (from 38 fewer to 3 more) deaths per 1000 patients (very
low certainty).84 Intermediate-intensity anticoagulation may re-
duce the risk of PE in critically ill patients but the evidence is very
uncertain (adjusted OR, 0.09; 95% CI, 0.02-0.57); this corre-
sponds to 15 fewer (from 16 fewer to 7 fewer) PEs per 1000
patients (very low certainty).70 Intermediate-intensity anticoagu-
lation may reduce the risk of DVT in critically ill patients but the
evidence is very uncertain (OR, 0.35; 95% CI, 0.06-2.02); this
corresponds to 13 fewer (from 18 fewer to 19 more) DVTs per
1000 patients (very low certainty).69
Harms and burden. One cohort study showed that therapeutic-
intensity anticoagulation may increase the risk of major bleeding
(adjusted hazard ratio, 3.89; 95% CI, 1.90-7.97),83 and 1 matched
case-control study reported a higher use of therapeutic-intensity
anticoagulation in the groups with upper gastrointestinal bleeding
(OR, 1.84; 95% CI, 0.49-6.98) and lower gastrointestinal bleeding
(OR, 1.42; 95% CI, 0.14-15.02),82 but the evidence from both
studies was very uncertain. Taking the range of point estimates, this
translates into 7 to 46 more major bleeding events per 1000
patients (very low certainty due to risk of bias and imprecision).
However, the panel also considered a plethora of indirect evidence
in non–COVID-19 acutely ill patients demonstrating a dose-
dependent effect of anticoagulation on bleeding risk.71-74
Other EtD criteria and considerations. The guideline panel
noted that there was possible uncertainty and variability in the
relative value patients place on reducing thrombotic events
compared with avoiding major bleeding events. The panel agreed
that the use of intermediate-intensity or therapeutic-intensity anti-
coagulation would be acceptable to patients and health care
providers. However, given the very low certainty in the evidence,
there may be regional variation in the acceptability of higher-dose
anticoagulation, particularly in regions where baseline VTE risk may
be lower (eg, Asian populations).75,76
The panel recognized that COVID-19 disproportionately affects
certain racial and ethnic groups, including Black and Hispanic
individuals. However, the use of intermediate-intensity or therapeutic-
intensity anticoagulation was not felt to have a differential impact
on health equity relative to the use of prophylactic-intensity anti-
coagulation. Although higher-intensity anticoagulation would result in
a higher drug cost, the panel judged this difference to be negligible
relative to the total costs of providing acute medical care.
Conclusions for this recommendation. The panel judged
that there was very low–certainty evidence in the desirable and
undesirable effects of intermediate-intensity or therapeutic-intensity
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anticoagulation for patients with COVID-19–related acute illness.
The baseline risk of mortality, VTE, and major bleeding for patients
with COVID-19–related acute illness receiving prophylactic-
intensity anticoagulation was relatively low, leading to small
absolute-risk differences for patients receiving intermediate-
intensity or therapeutic-intensity compared with those receiving
prophylactic-intensity anticoagulation.
There was a suggestion of mortality benefit and reduction in VTE
with intermediate-intensity or therapeutic-intensity anticoagula-
tion, but this evidence was of very low certainty. Meanwhile, there
was less uncertainty in the potential undesirable effects of
intermediate-intensity or therapeutic-intensity anticoagulation in
increasing the risk of major bleeding complications. The panel
considered that there was higher-quality indirect evidence from
non–COVID-19 acutely ill patients for a dose-dependent increase
in the risk of major bleeding with anticoagulation, although the
magnitude of this effect was uncertain in the COVID-19 population.71-74
Given that there was very low certainty for benefit to offset
themoderate risk of major bleeding complications, the usual practice of
prophylactic-intensity anticoagulation in acutely ill non–COVID-19
patients was suggested.39
The panel, however, recognized the potential for benefit and noted
that an individualized decision is important for each patient based on
an assessment of thrombosis and bleeding risk. Risk-assessment
models have been developed for hospitalized patients without
COVID-19 for estimation of thrombosis and bleeding risk, but these
models have not been validated in the hospitalized COVID-19
population.40,44,45 For patients judged to be at high thrombotic
risk with low bleeding risk, panel members acknowledged that
higher-intensity anticoagulation could be considered. Dose
adjustment of prophylactic-intensity anticoagulation for extremes
of body weight or renal impairment may also be considered.
What are others saying and what is new in
these guidelines?
There are several recently published guidance documents that focus
primarily on the use of anticoagulation for patients with COVID-19.
These include the 2020 CHEST COVID-19 Guidelines, the Anti-
coagulation (AC) Forum interim clinical guidance, the International
Society on Thrombosis and Haemostasis (ISTH) Scientific and
Standardization Committee (SSC) COVID-19 clinical guidance, and
the American College of Cardiology (ACC) clinical guidance.85-88
Major differences between the current ASH guidelines and these
other documents include use of high-quality systematic reviews and
EtD frameworks, which increase transparency, along with use of
marker states to estimate the relative importance to patients as key
outcomes of treatment. In addition, although the current ASH
guidelines focused on only 2 clinical questions, the other 4 guidelines
were broader in the clinical questions that were addressed.
The CHEST guidelines are similar to the current ASH guidelines in that
they recommend standard prophylactic-intensity anticoagulation over
higher-intensity for both acutely ill and critically ill patientswith COVID-19.
However, although the current ASH guidelines do not suggest 1
specific anticoagulant over another due to lack of direct evidence, the
CHEST guidelines favor low-molecular-weight heparin over unfractio-
nated heparin in order to limit staff exposure to patients with COVID-19
(although the ASH panel acknowledges the importance of limiting staff
exposure when selecting an anticoagulant). The CHEST guidelines
also caution against the use of direct oral anticoagulants for patients
hospitalized with COVID-19 due to concerns about possible drug
interactions with other adjunctive therapies, and the risk of rapid clinical
deterioration, which may impact on bleeding risk. The CHEST
guidelines also explicitly recommend against the routine use of
systemic thrombolysis for patients with COVID-19 who develop PE
without hemodynamic compromise.89 The current ASH guideline
does not address the question of systemic thrombolysis in this
context, nor was this question prioritized by the guideline panel.
Other areas addressed by the CHEST guidelines that were not
specifically addressed by the ASH guideline panel include
postdischarge thromboprophylaxis and the role of screening
ultrasound in asymptomatic patients with COVID-19.
The AC Forum interim clinical guidance recommends that acutely ill
patients receive standard prophylactic-intensity anticoagulation,
with dose adjustments according to the patient’s age and renal
function. However, in contrast to the current ASH COVID-19
guideline, the AC Forum suggests that critically ill patients should
receive increased doses of VTE prophylaxis (intermediate-intensity)
based largely on expert opinion, along with extrapolation from
indirect evidence for efficacy and safety of such regimens in
bariatric surgery, trauma, and influenza-related critical illness.90-92
The AC Forum document includes suggestions on thrombopro-
phylaxis in the setting of pregnancy, monitoring strategies for
parenteral anticoagulation therapy, and thrombolytic therapy for
acute respiratory distress syndrome. The AC Forum also recom-
mends against serial monitoring of D-dimers, and recommends
against intensification of anticoagulant dosing based on D-dimer
concentration. The D-dimer as a prognostic factor for thrombotic
risk and mortality is not addressed in the present ASH guideline.
The ISTH-SSC interim guidance in hospitalized patients with COVID-
19 also suggests that acutely ill and critically ill patients should
receive standard prophylaxis doses of low-molecular-weight heparin
or unfractionated heparin, although intermediate-intensity low-
molecular-weight heparin may be considered for patients judged to
be at high VTE risk. The ISTH-SSC also explicitly suggests against
the use of therapeutic-intensity anticoagulation until data are available
from randomized trials that are currently being conducted. In addition,
the ISTH-SSC document also suggests that multimodal thrombo-
prophylaxis, includingmechanical methods (ie, intermittent pneumatic
compression), should be considered in conjunction with antico-
agulation therapy in critically ill patients with COVID-19. This is
notable as current guidelines in critically ill non–COVID-19 patients
suggest using pharmacological prophylaxis alone over combined
pharmacological and mechanical prophylaxis, which is also reflected
in a recent large randomized trial.39,93 These differences speak to the
urgent need for more high-quality data on baseline thrombosis risk in
COVID-19–related critical illness.
Finally, the ACC guidance document also suggests that hospital-
ized patients with COVID-19 should receive prophylactic-intensity
anticoagulation. This recommendation applies to patients who do not
have disseminated intravascular coagulation (DIC), and to those with
DIC who do not have evidence of bleeding. The current ASH
guidelines do not make recommendations based on specific
thrombotic or bleeding risk factors such as DIC, as it remains unclear
whether these factors are predictive of clinical outcomes in COVID-19.
Although early observational studies were suggestive of clinical benefit
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when heparin was given to patients with COVID-19 who had an
elevated D-dimer or sepsis-induced coagulopathy,94 there remain
no high-quality randomized data addressing this question. The
ACC document also contains recommendations on manage-
ment of COVID-19 and acute coronary syndrome and post-
discharge thromboprophylaxis, which are not addressed in the
current ASH guideline.
Limitations of these guidelines
The limitations of these guidelines are inherent in the very
low–certainty in the evidence we identified for the research
questions. In addition, there were several outcomes that were
identified as critical for decision-making by the guideline panel for
which no direct evidence was available. This limited the breadth of
outcomes that were available to panel members to inform their
judgments and recommendations. These outcomes included
multiple organ failure, ischemic stroke, intracranial hemorrhage,
invasive mechanical ventilation, limb amputation, ICU hospitalization
(duration), and ST-elevation myocardial infarction.
Revision or adaptation of the guidelines
Plans for updating these guidelines
After publication of these guidelines, ASH will maintain them
through surveillance for new evidence, ongoing review by experts,
and regular revisions. These recommendations will be updated
based on a living review of evolving evidence, including data from
randomized trials that have recently been published95 or are actively
recruiting patients at the time of this manuscript. Systematic reviews
will be updated on a monthly basis, and new meta-analyses will be
conducted when explicit criteria are met. The living guideline panel
will be informed about whether published recommendations should
be reassessed based on changes that occur in the balance of
benefits and harms, the quality of evidence available, or other
factors (eg, costs, feasibility, acceptability, equity) (supplemental
File 1). These living recommendations will be developed using the
GRADEpro EtD to make judgments on the evidence.
Updating or adapting recommendations locally
Adaptation of these guidelines will be necessary in many circum-
stances. These adaptations should be based on the associated
EtD frameworks.13
Priorities for research
On the basis of gaps in evidence identified during the guideline-
development process, the panel identified the following urgent
research priorities in this patient population:
c studies assessing baseline VTE risk in critically ill and acutely ill
patients on prophylactic-intensity anticoagulation therapy;
c randomized controlled trials comparing anticoagulation at differ-
ing intensities (prophylactic vs intermediate vs therapeutic);
c studies examining the impact of nonanticoagulant interventions
(eg, anticomplement therapy, corticosteroids, antiviral therapies,
anticytokine therapies, antiplatelet therapies, monoclonal anti-
body therapy, convalescent plasma) on thrombotic risk;
c development or validation of risk-assessment models for throm-
bosis and bleeding for patients with COVID-19–related critical
illness and acute illness;
c studies examining the impact of anticoagulant therapy on
thrombosis and bleeding outcomes for patients of differing
race/ethnicity;
c studies examining the impact of anticoagulant therapy on
thrombosis and bleeding outcomes in pediatric and pregnant
patients; and
c studies comparing mortality, thrombosis, bleeding, and func-
tional outcomes with different available anticoagulant agents.
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